SNIPR enrolls first patient in Phase 2 SNIPR001 trial
The study expands to 66 patients, after Phase 1 completion in healthy subjects and dosing of 25 patients in Part 1.
See the latest news and media coverage for SNIPR. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing CRISPR-based medicines for bacterial infections
sniprbiome.comLast updated
In short: SNIPR enrolled the first patient in its Phase 2 SNIPR001 trial.
The study expands to 66 patients, after Phase 1 completion in healthy subjects and dosing of 25 patients in Part 1.
Director of Phage Engineering Y. Emre Gencay presents Phase 1 safety, recovery and pharmacodynamics results for the CRISPR-armed phage cocktail targeting E. coli on 8 July in Prague
New investors the Cystic Fibrosis Foundation and German agency SPRIN-D join existing backers Lundbeckfonden BioCapital, North-East Family Office and Wellington Partners.
The financing, backed under HERA Invest as part of the European Commission's InvestEU initiative, funds medicines for infections where antibiotics fail.
Copenhagen-based SNIPR Biome, a BioTech company innovating the development of microbial CRISPR-medicine, announced the close of a €35 million Series B raise to advance CRISPR-based...
COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of...
EIB lends up to €20 million to Danish clinical-stage biotech SNIPR Biome to develop new medicines for infections that are difficult to treat due to...
COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food...
Track SNIPR and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to SNIPR and other trending companies.